Blood cancer treatment is entering a new era, bringing powerful breakthroughs that offer renewed hope to people living with leukemia, lymphoma, myeloma, and other blood cancers. Cutting-edge targeted ...

Scientists announced two major molecular genetics breakthroughs: a targeted antibody-drug conjugate for acute myeloid leukemia and a CRISPR-based diagnostic that distinguishes multiple viruses by ...

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy ...

Preclinical study results suggest that targeting Hippo signaling may help address treatment resistance in acute myeloid ...

Scientists have detailed advances in targeted acute myeloid leukemia therapy, CRISPR-based virus detection, and the role of water molecules in gene transcription. These findings demonstrate new ways ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I think that the last year to two years ...

CPX-351 improved overall survival among older patients with myelodysplastic-related AML who undergo hematopoietic transplantation. CPX-351 treatment resulted in improved overall survival (OS) among ...

Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...

As blood cancers are constantly evolving and developing mutations that grow resistance to current treatments, researchers in the University of Cincinnati Cancer Center's Leukemia and Drug Development ...

(RTTNews) - Ipsen (IPSEY, IPN.PA) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza ...